Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swedish Orphan, Under Pressure At Home, Looks to Commerical Swap With China Company For Growth

This article was originally published in PharmAsia News

Executive Summary

Swedish Orphan Biovitrum AB and partner Dongbao Enterprise Group Co.. have identified intravenous iron for anemia as the first product to be included in their previously announced commercial alliance. The move comes as SOBI ended its deal to distribute Amgen's Mimpara (cinacalcet) in the Nordic territories, the second time it has returned Scandinavian marketing rights to a partner in the past three months

You may also be interested in...



Korea's BL&H To Distribute Swedish Orphan Biovitrum's Orphan Disease Products

SEOUL - South Korean drug importer and distributor BL&H inked a distribution deal with Swedish Orphan Biovitrum for the latter's two orphan disease products Orfadin and Kepivance in Korea

Korea's BL&H To Distribute Swedish Orphan Biovitrum's Orphan Disease Products

SEOUL - South Korean drug importer and distributor BL&H inked a distribution deal with Swedish Orphan Biovitrum for the latter's two orphan disease products Orfadin and Kepivance in Korea

Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma

Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel